Long term positivity of SARS-CoV-2 total immunoglobulins in convalescent plasma and blood donors

Running title: Evolution of SARS-CoV-2 antibodies

M Carmen Martín^a

Ana Jimeneza

Nuria Ortega^a

Alba Parrado^a

Isabel Page^a

M Isabel González^a

Lydia Blanco-Peris^a

^aCentro de Hemoterapia y Hemodonación de Castilla y León

Keywords: total immunoglobulins, SARSCoV2, seroprevalence, blood donors

Corresponding author: M Carmen Martín; cmartinalo@saludcastillayleon.es; Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos s/n, 47007 Valladolid, Spain

Conflicts of interests

MCM participates as lecturer in a sponsored symposium managed by Roche Diagnostics. No other conflicts have been identified.

Sources of research support

This work has been supported by Roche Diagnostics International Ltd., who provided free equipment and test reagents. Roche Diagnostics International Ltd. was not involved, either in study design, collection, analysis and interpretation of data, the writing of the report or in the decision to submit the article for publication.

Acknowledgements

LB and MCM conceived and designed the study. NO and AP acquired data, IP, AJ and MIG performed analysis and interpretation of laboratory data, MCM and LB drafted the article and revised it critically for important intellectual content, all authors provided final approval of the version to be submitted.

The authors thank to all blood donors for making this work possible by allowing research use of their samples by the Biobanco del Centro de Hemoterapia y Hemodonación de Castilla y León. They also thank the staff in charge of blood donation, and lab technicians for their efforts and from Roche Diagnostics International Ltd. for its support.

Long term positivity of SARS-CoV-2 total immunoglobulins in convalescent plasma

and blood donors

Abstract

Background: One of the most questioned issues about SARS-CoV2 immunity is

how long does it last. Whether lasting differences exist between infection and

vaccination boosted immunity is yet to be known. The answer to this question will

determine key issues such as the reliability of individual and herd immunity or the

need of sanitary restrictions or periodical revaccination. The aim of this study

was to determine how long total anti SARS-CoV2 antibodies due to past infection

persist in peripheral blood and whether sex, age or haematological features can

influence their lasting.

Material and Methods: A total of 2432 donations SARS-CoV-2 from 662 repeat

donors from April 2020 to February 2021 were analysed. Donors were 69.7%

males and their average age was 46. An automated chemilumiscence

immunoassay for total antibodies recognizing N protein of SARS-CoV-2 in human

serum and plasma was performed.

Results and discussion: In 97.6% donors with follow-up, anti SARS-CoV-2

protein N total antibodies remained positive up to 46 weeks after first positive

determination. Blood group was not related to antibody waning. Lower

lymphocyte counts and higher neutrophils and as well higher seric IgA would help

predict future negativization of antibodies. The vast majority of donors keep their

total immunoglobulins anti SARS-CoV-2 positive for longer than 10 months.

Ageing might have a protective effect against antibody waning but, given the

small number of cases that become negative, more studies, or larger cohorts

would be needed to confirm these facts.

Keywords: COVID-19, antibodies, immunity, immunoglobulins, SARS-CoV-2

Introduction

- 2 One of the most questioned issues about SARS-CoV2 immunity is how long does
- 3 it last. Although evidence exists of SARS-COV-2 infection inducing long-lived
- 4 bone marrow specific plasma cells even in mild cases [1], it's not yet established
- 5 whether infection or vaccination boosted immunity will last as long. The answers
- 6 to this question would determine key issues such as the reliability of individual
- 7 and herd immunity or the need of sanitary restrictions or periodical revaccination.
- 8 Most SARS-CoV-2 infected individuals develop an effective immune response,
- 9 leading to viral eradication and the production of specific T cell responses and
- antibodies against SARS-CoV-2 that are usually detectable 10-21 days after
- 11 infection [2,3].
- Antibody assays are not equivalent: they either detect antibodies against different
- viral proteins (S1, S1/S2, RBD or NC) or different immunoglobulin classes: IgG,
- 14 IgM, IgA or their combinations. Many factors can influence test performance,
- including cross-reactivity with other coronaviruses, that can occur in up to 28%
- individuals [2] or platform (laboratory-based vs point-of-care, lateral flow).
- 17 Chemiluminiscence assays have suitable performances regarding both sensibility
- and sensitivity and correlate with titres of neutralizing antibodies [4].
- Antibody responses against viral S and N proteins are equally sensitive in the
- 20 acute phase of infection, but antibody responses against N seem to wane in the
- 21 post infection phase whereas those against the S protein would persist over time
- 22 with a slow decay [1, 5]
- Even if antibody levels waned, long-lived mononuclear blood cells (MBCs) and
- long-lived bone marrow plasma cells would remain to mediate rapid antibody
- 25 production triggered by a new contact with the virus. Some studies suggest that
- 26 SARS-CoV-2 infection strengthens pre-existing broad coronavirus protection
- through S2-reactive antibody and MBCs formation [6]
- Antibody evolution surveys are most useful to monitor the pandemic, both before
- and after vaccination strategies [7]. There are several features that should be
- 30 taken into account, including time lapse between infection and antibody

31 development or antibody waning. Blood donors constitute a representative

subset of population aged 18-65 and are reasonably free of biases that could

over represent symptomatic or exposed individuals.

Heterogeneity of susceptibility and transmission is hard to evaluate but does exist

[8]. A portion of the population may have pre-existing immunity via cross-

reactivity or particular host factors such as mucosal immunity or trained innate

immunity protection (as it has been reported to be conferred by Diphtheria-

pertussis-tetanus (DPT) or Bacillus Calmette-Guérin (BCG) vaccination [9].

There is as well a proportion of post infection seronegative individuals that

develop immunity by T cell mediated responses but without exhibiting an

41 antibody response [10].

32

33

35

36

37

38

39

40

43

44

45

46

47

48

49

50

52

53

54

55

56

58

59

60

61

62

To date it is not possible to ascertain whether antibodies can last longer than the

time COVID-19 has been among us. There are recently described early cases in

France [10], arising the question of whether the pathogen could have been

circulating even before the recording of the first cases in Spain by January 31st,

2020. Our fist positive donations are from 2019, possibly due to cross-reaction to

previous coronaviruses [11] but we decided to start our series on January 13th,

the donation date of our first positive after WHO issued a comprehensive

package of technical guidance online with advice to all countries on how to

detect, test and manage potential cases.

51 Our starting hypothesis was that the vast majority of either recovered or

asymptomatic SARS-CoV-2 cases would develop and keep antibodies against

the novel coronavirus [1, 2, 9]. They will subsequently contribute to herd

immunity. Anyone holding antibodies due to prior infection, should be kept from

receiving the second dose of vaccines requiring booster, so far their cellular

response could even result impaired [12].

57 The main aim of this study was to determine which percentage of the

seropositive population due to natural infection keeps total antibodies recognizing

SARS-CoV2 and how long can they last. A secondary goal was to establish

whether sex, age, blood group or haematological features might influence the

fact of keeping or loosing circulating antibodies. This knowledge would help

optimize immunization strategies, and would ease decisions about the need of

periodical revaccination either overall or for determined population groups by

reliably knowing the lasting of specific humoral immunity.

METHODS

63

64

65

67

68

69

72

73

74

75

76

77

78

80

81

82

83

86

87

88

89

90

91

92

93

94

The aim of this study was to determine how long anti SARS-CoV2 antibodies

persisted in peripheral blood, and whether haematological o demographical

parameters would be related to it. A retrospective testing and information

compilation was performed

70 Plasma-EDTA and serum frozen samples from blood, plasma (normal and

71 convalescent) and platelet donations were tested. A total of 2432 aleatorized

samples of 662 donors over 18 years old were included. Donation is allowed after

one month after the end of COVID-19 symptoms in our country. The Biobank of

the Centro de Hemoterapia de Castilla y León is included in the National Registry

of Biobanks (RD17 / 16/2011) with the number B.0000264 and holds an ISO

9001: 2015 certification endorsing our granting of safety and traceability of any

human biological sample we distribute, always behaving Spanish and European

rules on human samples and data protection management.

79 All haematological and demographic data were extracted from electronic

database eDelphyn (Hemasoft). Variables analyzed included age, sex, blood

group, and laboratory data: leukocyte (WBC), neutrophil, lymphocyte, platelet,

monocyte, eosinophil and basophil counts (cells*10³/µL) and their percentages,

serum immunoglobulins IgG, IgA and IgM (mg/dL), haemoglobin (Hb) and

84 haematocrit (HCT).

85 An automated chemiluminiscence double-antigen sandwich immunoassay for the

in vitro semi quantitative detection of total antibodies to SARS-CoV-2 in human

serum and plasma was performed. The target antigen of this immunoassay is a

recombinant nucleocapsid (N) protein. Elecsys® Anti-SARS-CoV-2 (Roche

Diagnostics, Basel, Switzerland) detects antibodies correlating with virus-

neutralizing ones and is therefore useful to help characterize the immune

reaction to SARS-CoV-2 [9, 10]. Immunoassay was validated by our serology lab

by testing of 6 pairs of samples (plasma EDTA and serum) from diagnosed PCR-

positive, symptomatic cases infected by mid-April, that were previously reported

positive by the Spanish National Microbiology Centre, and checked to be as well

positive for IgG (Chemiluminiscence, N protein, Abbott Alinity S, Chicago USA) 95 and IgA (ELISA, S protein, Euroimmunn, Lübeck, Germany) antiSARS-CoV-2. 96 Another set of ten prepandemic samples, therefore supposed to be negative, 97 were equally analysed. 405 donations were analysed both in serum and plasma 98 to verify interchangeability. A 100% concordance was yielded by all these 99 validation assays. The cut-off was that recommended by manufacturer (OD>1 to 100 report reactivity). Researchers performing anti SARS-CoV-2 analyses were blind 101 to the condition of COVID-19 convalescence and to any other characteristic of 102 103 the donors or to the donation dates. Demographic and clinical characteristics of patients are expressed as their mean 104 105 and standard deviation (SD) for continuous variables and frequency distributions are reported for categorical variables. Age was analysed both as continuous and 106 107 categorical variable; in the latter case was recoded into 4 groups: under 30, ≥30 and <45, ≥45 and <60, and, last, ≥60 and >75 years old. 108 Donors whose second OD were under 90% of the first of that of their first positive 109 were recoded into decay group. Donors over 110% were recoded as rise and 110 those who were +/-10% of the first one were in the stay group. 111 112 Kolmogorov-Smirnov test was performed on each continuous variable to contrast normality. None of the variables followed normal distributions, therefore non-113 parametric Mann Whithney U test was performed to compare laboratory values. 114 To contrast the Ho of independence within categorical variables, Pearson's Chi-115 square and Fisher's exact test were carried out. Any test was considered to be 116 significant at a 95% confidence level. 117 This study was conducted according with national regulations, institutional 118 policies and in the tenets of the Helsinki Declaration, it was approved by the 119 Valladolid Health Area Drug Research Ethics Committee, in a meeting held on 120 June 11th, 2020 with the reference number "BIO-2020-93". Included donors 121

Results

human subjects were always observed.

122

123

124

126

A total of 2432 donations (either whole blood, plasmapheresis or platelet


apheresis) were tested for total anti SARS-CoV2 antibodies recognizing N

consented to participate in Biobank research activities. The privacy rights of

protein. Donors made up 662; 69.7% males, aged 18-75, average 46+/-12, 46.3% A, 43.1% O, 6.5% B, 4.1 % AB. Donations were selected at random among those collected from 13th January 2020 (date of the first 2020 positive found) to 11th February 2021.

250 donors were positive at least once (provided a second donation after the positive one was analyzed) and therefore their 340 donations selected for further analysis. 62 donors had more than 2 positive donations. Average time gap between samples was 12.31 weeks (1-46, SD=10.01).

We considered the first positive sample of the donor within the assessed period as first donation of this study. Out of the 250 initially positive donors, only 6 (2.4%) became negative at any moment of their follow-up (Figure 1).



positive, second, negative; decay: OD of second donation under 90% of the first one; stay: OD of second donation +/-10% of the first one; rise: OD of second donation over 110% of the first one)

Only 6 out of 250 donors lost their antibodies, all of them after just one positive donation. They were two males in their fifties and four women, two in their fifties again and two younger ones (Table1). No other wane events were found. All waning cases were weak positives (OD <2.5) in their first positive donation.

				DO1	DO2	Weeks
Sex	n	Age group	Blood group	(mean(SD))	(mean(SD))	(mean(SD))
Male	2	≥45 and <60	Α, Ο	1.51 (0.59)	0.55 (0.05)	12 (1.41)
Female	1	under 30	Α	1.05 (-)	0.88 (-)	26 (-)
	1	≥30 and <45	Α	1.08 (-)	0.56 (-)	14 (-)
	2	≥45 and <60	0	1.06 (0.02)	0.72 (0.23)	20 (8.49)

Table 1. Characteristics of donors loosing anti SARS-CoV-2 antibodies, optical density (OD) and interval between positive and negative donations (weeks) with total immunoglobulin to SARS-CoV2 becoming negative (OD1: optical density of first positive donation, OD2 optical density of consecutive donation to the first positive one)

97.6% donors kept positive their total antibodies against SARS-CoV-2. The longest period lapse between first and last donation was 46 weeks. No relationship with age, blood group or sex was found. Neither was found as comparing raw OD values.

No relationship of waning or OD changes due to blood group (Table 2) was found. Rising OD was less frequent within the under 30 group as a trend (OR=0.4; CI (0.13-1.21); p=0.149). Waning was more frequent in women as a trend (OR=3.56; CI (0.64-19.8)).

			Fact			Trend						
		Wa	ane	keep		de	decay		rise		stay	
		n	%	n	%	n	%	n	%	n	%	
Gender	Female	4	4,4%	87	95,6%	50	54,9%	22	24,2%	19	20,9%	
	Male	2	1,3%	157	98,7%	90	56,6%	32	20,1%	37	23,3%	
Group	Α	3	2,4%	124	97,6%	75	59,1%	22	17,3%	30	23,6%	
	AB	0	0,0%	16	100,0%	8	50,0%	5	31,3%	3	18,8%	
	В	0	0,0%	17	100,0%	9	52,9%	5	29,4%	3	17,6%	
	0	3	3,3%	87	96,7%	48	53,3%	22	24,4%	20	22,2%	
Age	under 30	1	2,8%	35	97,2%	25	69,4%	4	11,1%	7	19,4%	
	30 to 45	1	1,2%	80	98,8%	49	60,5%	17	21,0%	15	18,5%	
	45 to 60	4	3,3%	117	96,7%	60	49,6%	32	26,4%	29	24,0%	
	60 to 75	0	0,0%	12	100,0%	6	50,0%	1	8,3%	5	41,7%	

Table 2. Donor changes in seropositivity and OD for anti SARS-CoV-2 total immunoglobulins by sex, blood group and age group.

Haemogram parameters (leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, haematocrit and haemoglobin) from each donor were tested for its relationship with antibody waning (Table 2). Lymphocyte percent was significantly lower (25.4% vs. 31.7%; p=0.021) conversely to neutrophil percent (65.1 vs 59.1; p=0.024) in those donors whose antibodies would wane. IgA was found to be higher as a trend (324 vs. 227 mg/dL; p=0.153), as well as platelets (279.7 vs. 247.1; p=0.166) and neutrophil count (5.2 vs 4.2; p=0.129) (Table 3).

When an age-stratified analysis was performed, some facts become noticeable as regarding just the \geq 45 and <60 group: higher leukocytes arose as a significant difference in those who would wane (9.65 vs. 6.59; p=0.047), The difference in platelets is more evident as regarding just this group (327 vs. 231 p=0.019), the same happens with neutrophils both in absolute numbers (5.59 vs. 3.78; p=0.019) and percent (66.95 vs 58.25; p=0.014), lymphocyte count (1.86 vs 2.02; p=0.005), monocyte number (0.58 vs 0.41; p=0.028). Eosinophils were lower under 45: in under 30 group (0.02 vs 0.12 p= 0.049) and in \geq 45 and <60 group (0.23 vs.0.15; p=0.034) (Supplementary Table 1).

	wane	keep	decay	stay	rise
Age	+	-	+	1	-
IgA	•	1	-	1	1
Platelets	•	1	-	1	1
WBC	-	-	-	1	-
Neutrophil count	1	-	-	1	-
Neutrophil %	•	-	-	1	-
Lymphocyte count	1	-	-	+	-
Lymphocyte %	+	-	-	1	-
Basophil %	-	-	-	1	-

Figure 2. Significant changes in hematological parameters related to changes in anti SARS-CoV-2 total antibodies (wane: first donation positive, second, negative; decay: OD of second donation under 90% of the first one; stay: OD of second donation +/-10% of the first one)

			n	mean	SD	IQR
Age		Wane	6	43.8	9.6	34.7-50.1
	p=0.153	Keep	331	45.0	10.8	37.6-54.1
IgA		Wane	5	324.4	149.3	191-443
		Keep	164	227.3	82.5	166-274
IgG		Wane	5	1003.4	122.2	892-1092
		Keep	164	1053.3	166.2	955.5-1153
IgM		Wane	5	101.2	41.6	85-138
		Keep	164	121.2	63.1	78-151.5
WBC count		Wane	5	8.1	2.7	6.8-9.7
		Keep	326	7.0	1.8	5.8-7.9
Platelets		Wane	6	279.7	56.6	43.3-48.4
		Keep	328	247.1	51.4	42.9-47.3
Haematocrit		Wane	6	46.1	3.8	226-328
		Keep	328	45.1	3.0	211.5-274.5
Neutrophil count		Wane	6	5.2	1.9	43.3-48.4
	p=0.129	Keep	328	4.2	1.5	42.9-47.3
Neutrophil %	*	Wane	6	65.1	4.9	226-328
	p=0.024	Keep	328	59.1	7.8	211.5-274.5
Lymphocyte count		Wane	6	1.9	0.4	4.4-6.7
		Keep	328	2.2	0.6	3.2-4.8
Lymphocyte %	*	Wane	6	25.4	6.1	64.7-68.9
	p=0.021	Keep	328	31.7	7.0	54-63.9
Monocyte count		Wane	6	0.5	0.2	1.7-2
		Keep	328	0.4	0.1	1.8-2.5
Monocyte%		Wane	6	6.3	0.7	20.9-26.8
		Keep	328	6.2	1.3	27.5-36.3
Eosinophil count		Wane	6	0.2	0.2	0.4-0.7
		Keep	328	0.2	0.1	0.3-0.5
Eosinophil %		Wane	6	2.9	2.7	5.8-6.7
		Keep	328	2.4	1.7	5.3-7.1
Basophil count		Wane	6	0.0	0.0	0.1-0.3
		Кеер	328	0.0	0.0	0.1-0.2
Basophil %		Wane	6	0.5	0.1	1.8-2.8
		Кеер	328	0.5	0.3	1.3-3.1

Table 3. Age and laboratory data in donations keeping or waning antibodies Wane: present donation positive, next one, negative; keep: both positive

192

193

ODs decayed as considering consecutive pairs of donations in 140 donors (56.0%, mean lapse between analysis, 9.5 weeks), rose in 54 (21.6%, mean lapse 11 weeks) cases and stayed +/-10% in 56 (22.4%, mean lapse 5.43 weeks) donors (Figure 1, Table 4). Donors whose ODs decayed were significantly younger (43 vs 47; p=0.042). The ones whose OD due to anti SARS-CoV-2 total antibodies stayed +/-10% had lower IgA as a trend (191.5mg/dL vs. 224.3 or 227.5 mg/dL; p=0.048) and a higher percent of basophils (0.6% vs. 0.5%; p=0.146)

		n	mean	SD	IQR
Age	decay	202	43.7	45.0	10.8-36.2
*p=0,042	stay	74	46.5	47.4	10.8-39.4
	rise	60	47.5	49.7	10.3-40.4
IgA	decay	101	243.2	227.0	92.5-167
*p=0,048	stay	35	197.6	184.0	69-151
	rise	33	224.7	208.0	73.2-172
IgG	decay	101	1067.1	1071.0	165.8-973
	stay	35	1021.3	1012.0	176.3-836
	rise	33	1037.3	1061.0	148.6-940
lgM	decay	101	115.6	107.0	57.1-78
	stay	35	130.7	109.0	72-87
	rise	33	125.1	112.0	68.1-74
WBC count	decay	198	7.1	6.8	1.8-5.8
	stay	74	6.8	6.7	1.7-5.7
	rise	58	6.9	6.6	1.7-5.7
Platelets	decay	200	249.9	236.0	53.9-212
	stay	74	242.3	242.0	45.2-213
	rise	59	245.7	234.0	51.2-204
Hematocrit	decay	200	45.2	45.2	3-43.2
	stay	74	44.8	45.3	2.9-42.6
	rise	59	45.3	44.5	3.3-42.8
Neutrophil count	decay	200	4.3	4.1	1.6-3.2
	stay	74	4.1	3.8	1.5-3.3
	rise	59	4.0	3.7	1.2-3.1
Neutrophil %	decay	200	59.7	60.0	8-54.7
	stay	74	59.3	59.0	7.8-54
	rise	59	57.4	56.7	6.8-53
Lymphocyte count	decay	200	2.2	2.1	0.6-1.8
	stay	74	2.0	2.0	0.4-1.7
	rise**	59	2.3	2.1	0.7-1.8
Lymphocyte %	decay	200	31.2	31.3	7.3-26.6
	stay	74	31.2	31.2	6.8-26.4
	rise**	59	33.5	33.3	6.1-29.4

Monocyte count	decay	200	0.4	0.4	0.1-0.3
	stay	74	0.4	0.4	0.1-0.4
	rise	59	0.4	0.4	0.1-0.3
Monocyte %	decay*	200	6.2	6.0	1.3-5.3
	stay	74	6.4	6.4	1.2-5.7
	rise	59	6.2	6.3	1.2-5.2
Eosinophil count	decay	200	0.2	0.1	0.1-0.1
	stay	74	0.2	0.1	0.1-0.1
	rise	59	0.2	0.1	0.1-0.1
Eosinophil %	decay	200	2.4	1.9	1.8-1.3
	stay	74	2.5	2.0	1.7-1.3
	rise	59	2.4	2.1	1.5-1.3
Basophil count	decay	200	0.0	0.0	0-0
	stay	74	0.0	0.0	0-0
	rise	59	0.0	0.0	0-0
Basophil %	decay	200	0.5	0.5	0.3-0.4
p=0,146	stay	74	0.6	0.5	0.3-0.4
	rise	59	0.5	0.5	0.2-0.4

Table 4. Age and laboratory donation data layered by OD observed changes in total anti SARS-CoV-2 antibodies (rise: the second determination was over 110% of the first; stay: OD of the second donation was 90%-110% of the first one; decay: OD of the second donation was under 90% of the first one)

Discussion

There is little literature on SARS-CoV-2 antibody waning. Antibodies recognizing N protein of SARS-CoV-2 have been elsewhere reported to wane in the post infection phase while those against the S protein would persist over time [13]. Additionally, the antibody response would be robust in patients with severe infection and weaker in those with mild infection or asymptomatic individuals. Although 71% of repeat donors in this study were convalescent plasma donors, one of our limitations is that we cannot recall how many of them developed severe symptoms. Some reports at the beginning of pandemics pointed out that up to 40% asymptomatic cases could lose their antibodies after 6 weeks from acute infection [13] but our data don't support that statement. More recent studies [1] demonstrate that durable serum antibodies would be granted by long-lived plasma cells. Our study confirms that most individuals would keep their antibodies for 10 months or longer. Our results agree as well to others reporting a high percentage of individuals (above 75%) keeping antibodies positive for at least 9 months even when a titer decline is patent [14]. That would mean at least

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

50 weeks after contagion so far they're not allowed to donate until 1 month after resolution of symptoms. Specific immunoglobulins would became detectable within 5-7 days post infection and seroconversion would happen after 10-14 days. Detectable levels of neutralizing antibodies against SARS-CoV-2 have been shown to start declining within three months of infection, especially among mild and asymptomatic cases [15]. Accordingly, one half (56.0%, Figure 1) of our donors exhibit a decay in their OD from total immunoglobulins anti SARS-COV-2 assay although most of them remain positive. Antibody waning would be independent of blood group in our cohort. Specific anti SARS-CoV-2 immunoglobulin loss would be a rare event slightly more frequent in women and a decay would be more frequent in younger donors. Mature age would determine longer antibody half-life [14]. Ageing is one of the most important determinants in COVID-19 severity [16, 17] and it would have a role as well in humoral response keeping but larger cohorts and replication analyses should be performed to determine whether a an age-titer correlation exists because of the small rate of waning cases. Lower lymphocyte and higher neutrophil percent might indicate future antibody waning. High neutrophil/lymphocyte ratios are somehow related to impaired immune responses with a high inflammatory component and cytokine storm [18]. Our findings would reinforce the hypothesis of a not so robust response that would weaken in the medium term. Some of these changes are more evident in mid- aged cases, an ageing effect cannot be discarded but the low number of waning cases, and the fact that none of them was older than 51 keeps us from further ascertainments, even when it points out a very interesting topic for future analyses. Total, non-specific, high IqA together with higher platelet count and lower neutrophil count might precede antibody waning as well. It is well known that several infectious agents such as malaria have prothrombotic effects, which happen as well in bacterial sepsis [19]. It has been elsewhere reported an elevation of platelets and their activation and a lower number and activity of

neutrophils in COVID-19 cases irrespective of their severity [20] accordingly to our data. Secreted IgA is known to play a key role in SARS-CoV-2 immunity but very little is known on circulating IgA [21]. IgG in combination with IgM and IgA would have greater neutralization capacity than IgG alone, a broader repertoire of antibodies correlates with a stronger SARS-CoV-2 neutralization [22]. Initial plasmablast's response declines quickly, whereas IgA-producing plasma cells persist for years in mucosae [23]. It might explain that individuals mounting a strong IgA response would seem to loose antibodies, but it will be interesting to check out whether salivary IgA remains positive or not so far IgA antibodies are the major component of the neutralizing antibodies developed in response to SARS-CoV-2 infection [24] Lower lymphocyte counts and higher neutrophils and as well higher seric IgA would help predict future negativization of antibodies. The vast majority of donors keep their total immunoglobulins anti SARS-CoV-2 positive for longer than 10 months. Ageing might have a protective effect against antibody waning but, given the small number of cases that become negative, more studies, or larger cohorts would be needed to confirm these facts.

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

Bibliography

- Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, Hansen L, Haile A, Klebert MK, Pusic I, O'Halloran JA, Presti RM, Ellebedy AH. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021 May 24. doi: 10.1038/s41586-021-03647-4. Epub ahead of print. PMID: 34030176.
- Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020 Oct 1;183(1):158-168.e14. doi: 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14. PMID: 32979941; PMCID: PMC7427556.
- Michael P Busch, Mars Stone, Serosurveillance for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood Donor Populations, *Clinical Infectious Diseases*, Volume 72, Issue 2, 15 January 2021, Pages 254–256, https://doi.org/10.1093/cid/ciaa1116
- 4. Wouters E, Steenhuis M, Schrezenmeier H, Tiberghien P, Harvala H, Feys HB, van der Schoot E. Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary. Vox Sang. 2021 May;116(5):493-496. doi: 10.1111/vox.13060. Epub 2020 Dec 23. PMID: 33368373.
- 5. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, Farina A, Campos J, Hacker D, Lau K, Bosch BJ, Gonseth Nussle S, Bochud M, D'Acremont V, Trono D, Greub G, Pantaleo G. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J Virol. 2021 Jan 13;95(3):e01828-20. doi: 10.1128/JVI.01828-20. PMID: 33144321.
- Nguyen-Contant P, Embong AK, Kanagaiah P, Chaves FA, Yang H, Branche AR, Topham DJ, Sangster MY. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes

304 Broad Reactivity to the S2 Subunit. mBio. 2020 Sep 25;11(5):e01991-20. doi: 10.1128/mBio.01991-20. PMID: 32978311; PMCID: PMC7520599.

- 7. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. JAMA Netw Open. 2021 Jan 4;4(1):e2033706. doi: 10.1001/jamanetworkopen.2020.33706. PMID: 33399860; PMCID: PMC7786245.
- 8. Cañete PF, Vinuesa CG. COVID-19 Makes B Cells Forget, but T Cells
 Remember. Cell. 2020 Oct 1;183(1):13-15. doi:
 10.1016/j.cell.2020.09.013. Epub 2020 Sep 4. PMID: 32976799; PMCID:
 PMC7472965
 - Netea MG, van der Meer JW, van Crevel R. BCG vaccination in health care providers and the protection against COVID-19. J Clin Invest. 2021 Jan 19;131(2):e145545. doi: 10.1172/JCI145545. PMID: 33306484; PMCID: PMC7810495.
 - 10. Gallais F, Velay A, Nazon C, Wendling M, Partisani M, Sibilia J, et al. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. Emerg Infect Dis. 2021;27(1):113-121. https://dx.doi.org/10.3201/eid2701.203611
 - 11. Martín MC, González MI, Holgado N, Jimenez AI, Ortega N, Page I, Parrado A, Pérez M, Blanco-Peris L Sustained seroprevalence of anti SARS-CoV-2 total immunoglobulins in asymptomatic blood donors medRxiv 2021.04.28.21256242; doi: https://doi.org/10.1101/2021.04.28.21256242
 - 12. Camara C, Lozano-Ojalvo D, Lopez-Granados E, Paz-Artal E, Pion M, Correa-Rocha R, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals bioRxiv 2021.03.22.436441; doi: https://doi.org/10.1101/2021.03.22.436441

13. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin Virol.* 2020;129:104480. doi:10.1016/j.jcv.2020.104480

- 14. Varona JF, Madurga R, Peñalver F, Abarca E, Almirall C, Cruz M, Ramos E, Castellano-Vazquez JM. kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers. Eur J Intern Med. 2021 May 25:S0953-6205(21)00187-4. doi: 10.1016/j.ejim.2021.05.028. Epub ahead of print. PMID: 34090748; PMCID: PMC8148432.
- 15. Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Sci Immunol.* 2020;5(52):eabe5511. doi:10.1126/sciimmunol.abe5511
- 16. Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. Immun Ageing. 2020;17:22
- 17. Martín MC, Jurado A, Abad-Molina C, Orduña A, Yarce O, Navas AM, et al. The age again in the eye of the COVID-19 storm: evidence-based decision making. Immun Ageing. 2021 May 20;18(1):24. doi: 10.1186/s12979-021-00237-w. PMID: 34016150; PMCID: PMC8134808.
- 18.Imran MM, Ahmad U, Usman U, Ali M, Shaukat A, Gul N. Neutrophil/lymphocyte ratio-A marker of COVID-19 pneumonia severity. Int J Clin Pract. 2021 Apr;75(4):e13698. doi: 10.1111/ijcp.13698. Epub 2021 Jan 12. PMID: 32892477.
- 19. Marongiu F, Grandone E, Scano A, Orrù G, Marongiu S, Gerosa C, Fanni D, Faa G, Barcellona D. Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review. Eur Rev Med Pharmacol Sci. 2021 May;25(10):3886-3897. doi: 10.26355/eurrev_202105_25956. PMID: 34109597.
- 20. Chao Y, Rebetz J, Bläckberg A, Hovold G, Sunnerhagen T, Rasmussen M, Semple JW, Shannon O. Distinct phenotypes of platelet, monocyte, and neutrophil activation occur during the acute and convalescent phase of COVID-19. Platelets. 2021 May 17:1-11. doi: 10.1080/09537104.2021.1921721. Epub ahead of print. PMID: 33999778; PMCID: PMC8146300.

21. Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. *J Virol*. 2021;95(3):e01828-20. Published 2021 Jan 13. doi:10.1128/JVI.01828-20

- 22.Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med.* 2020;26(8):1200-1204. doi:10.1038/s41591-020-0965-6
- 23. Dos Santos JMB, Soares CP, Monteiro FR, et al. In Nasal Mucosal Secretions, Distinct IFN and IgA Responses Are Found in Severe and Mild SARS-CoV-2 Infection. *Front Immunol.* 2021;12:595343. Published 2021 Feb 25. doi:10.3389/fimmu.2021.595343
- 24. Noval MG, Kaczmarek ME, Koide A, et al. Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. *Sci Rep.* 2021;11(1):5538. Published 2021 Mar 10. doi:10.1038/s41598-021-84913-3

-36.4
-36.1
-36.3
-36.6
-0.5
-0.5
-0.5
-0.5
-7.1
7.1
-7.2
-7.3
0.0
-0.2
-0.2
-0.2
-0.2
2.4
-2.4
-2.7
-3.6
-2.6
-0
-0
0.1
).1).1
-0.6
-0.6
-0.6 -0.7
-0.7 -0.9

Supplementary Table 1. Laboratory data stratified by age in donations keeping or waning antibodies Wane: present donation positive, next one, negative; keep:

both positive

383

384

385